Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$306.68MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Benjamin Kovler
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 5,000
- Beta
- 0.92
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 1.99
Financials
Revenue
$306.68M+10059.6%Net Income
$4.88MEBITDA
$65.16MFree Cash Flow
$8.79MEPS (diluted)
$0.02Shares Outstanding (diluted)
222.78M+266637.2%Operating Expenses
$117.91MCash & Debt
$283.59MReturn of Capital
$50.89MRevenue by Segment (annual)
$1.18BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.18B | $116.15M | $0.50 |
| 2024 | $1.14B | $73.08M | $0.31 |
| 2023 | $1.05B | $36.27M | $0.15 |
| 2022 | $1.02B | $11.98M | $0.05 |
| 2021 | $893.56M | $75.44M | $0.33 |
| 2020 | $556.57M | $14.99M | $0.07 |
| 2019 | $216.43M | $-59.55M | $-0.31 |
| 2018 | $62.49M | $-7.86M | $-0.06 |
| 2017 | $16.53M | $-3.74M | $-44.81 |
| 2016 | $7.21M | $-979.7K | $-11.99 |
| 2015 | $0.00 | $-3.95M | $-58.10 |
| 2014 | $0.00 | $-686.8K | $-10.99 |
| 2013 | $0.00 | $-2.96M | $-48.45 |
| 2012 | $0.00 | $-23.27M | $-383.83 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.73
- Implied price
- $11.68
- Return from $6.61
- 12.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5.81 — -12.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -2.0% | -4.0% | -1.0% | 1.7% | 4.1% | 6.3% |
| 3.0% | 0.9% | 4.0% | 6.9% | 9.4% | 11.7% |
| 8.0% | 5.8% | 9.1% | 12.1% | 14.7% | 17.2% |
| 13.0% | 10.7% | 14.1% | 17.2% | 20.0% | 22.6% |
| 18.0% | 15.6% | 19.2% | 22.4% | 25.3% | 28.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+9.09%Social Signal Score
Mentions (9)
- Newsglobenewswire.com·13d ago·Positive
Green Thumb Industries to Report Third Quarter 2026 Financial Results on November 4, 2026 CHICAGO and VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced it will release third quarter 2026 financial results after the market closes on Wednesday, November 4, 2026.
View source ↗ - Newsglobenewswire.com·15d ago·Positive
… Program CHICAGO and VANCOUVER, British Columbia, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced that its board of directors authorized the continuation of the Company's share repurchase program for an additional 12 months, with up to $50 million available for share repurchases.
View source ↗ - Newsseekingalpha.com·22d ago·Positive
Green Thumb Industries Positioned For Growth In Virginia Rec Markets Green Thumb Industries Inc. is positioned for entry into Virginia recreational markets in 2027. The company recently reported in-line Q2 financial results with increasing revenue, net income, and free cash flow. GTBIF has plans to uplist to a major index after rescheduling is approved in the U.S.
View source ↗ - Newszacks.com·27d ago·Positive
Wall Street Analysts See a 103.26% Upside in Green Thumb Industries Inc. (GTBIF): Can the Stock Really Move This High? The consensus price target hints at a 103.3% upside potential for Green Thumb Industries Inc. (GTBIF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsglobenewswire.com·35d ago·Positive
Green Thumb Industries Announces Conference Attendance for September 2026 CHICAGO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries , today announced management will participate in the following conference in September 2026:
View source ↗ - Newsmarijuanastocks.com·35d ago·Positive
3 Marijuana Stocks To Focus On For Future Growth And Profits Marijuana stock investors are watching for new market potential. With all the new laws and changes, the possibilities to make money are there. Now, much of this sector has forever been one that is almost impossible to gauge. Meaning the volatility is so high that even the best company news may not impact trading like other public companies.
View source ↗ - Newsmarijuanastocks.com·42d ago·Neutral
3 Marijuana Stocks To Buy, Sell Or Trade This Year Investing in the best marijuana stocks that will make you money is always a challenge. Most of the cannabis sector is filled with unpredictable changes. Constant unforeseen variables make it too volatile for some to invest. Now, for those who are either new to marijuana stock investing or have weathered the storm, things have changed once more.
View source ↗ - Newszacks.com·46d ago·Positive
Can Green Thumb Industries Inc. (GTBIF) Run Higher on Rising Earnings Estimates? Green Thumb Industries Inc. (GTBIF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗ - Newsseekingalpha.com·58d ago·Positive
Green Thumb Industries: The Stock Is Priced Too Low For What It's Delivering, Jump In Green Thumb's quarterly revenue grew 4.6% during the quarter, while comps declined 1.1%, reflecting weak retail health of its existing stores. While the company's revenue grew consistently over the past 5 years, its EBITDA margin remained under pressure over the same period due to stiff competition. Overall, I give Green Thumb a buy rating. Low debt level, aggressive share buybacks, and Schedule III reclassific
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.03 per share
Typical surprise +100.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.02 vs $0.01beat
- Wed, May 6$0.07 vs $0.02beat
- Wed, Feb 25$0.35 vs $0.01beat
- Wed, Nov 5$0.10 vs $0.03beat
- Wed, Aug 6$-0.01 vs $0.04miss
- Wed, May 7$0.04 vs $0.05miss
Estimates and results for GTBIF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GTBIF officers and directors.
- Bought
- —
- Sold
- $10.0m
0 trades
2 trades
- Georgiadis Anthonysold
- Kovler Benjaminsold
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GTBIF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.